



NILDE

Network Inter-Library Document Exchange

Il presente documento viene fornito attraverso il servizio NILDE dalla Biblioteca fornitrice, nel rispetto della vigente normativa sul Diritto d'Autore (Legge n.633 del 22/4/1941 e successive modifiche e integrazioni) e delle clausole contrattuali in essere con il titolare dei diritti di proprietà intellettuale.

La Biblioteca fornitrice garantisce di aver effettuato copia del presente documento assolvendo direttamente ogni e qualsiasi onere correlato alla realizzazione di detta copia.

La Biblioteca richiedente garantisce che il documento richiesto è destinato ad un suo utente, che ne farà uso esclusivamente personale per scopi di studio o di ricerca, ed è tenuta ad informare adeguatamente i propri utenti circa i limiti di utilizzazione dei documenti forniti mediante il servizio NILDE.

La Biblioteca richiedente è tenuta al rispetto della vigente normativa sul Diritto d'Autore e in particolare, ma non solo, a consegnare al richiedente un'unica copia cartacea del presente documento, distruggendo ogni eventuale copia digitale ricevuta.

Biblioteca richiedente: Biblioteca del Polo universitario di Novara
Data richiesta: 25/10/2024 08:36:20
Biblioteca fornitrice: Biblioteca IRCCS materno infantile 'Burlo Garofolo' - Trieste
Data evasione: 25/10/2024 08:50:54

Titolo rivista/libro: Minerva ginecologica Online
Titolo articolo/sezione: Modern operative hysteroscopy
Autore/i: G. G. Centini
ISSN: 1827-1650
DOI:
Anno: 2016
Volume: 68
Fascicolo: 2
Editore:
Pag. iniziale: 126
Pag. finale: 132

REVIEW

HYSTEROSCOPY: CURRENT KNOWLEDGE AND FUTURE PERSPECTIVES

Modern operative hysteroscopy

Gabriele CENTINI, Libera TROIA, Lucia LAZZERI, Felice PETRAGLIA, Stefano LUISI *

Department of Molecular and Developmental Medicine, Obstetrics and Gynecology, University of Siena, Siena, Italy

*Corresponding author: Stefano Luisi, Department of Molecular and Developmental Medicine, Obstetrics and Gynecology, University of Siena, Policlinico "Le Scotte" Viale Bracci, 53100 Siena, Italy. E-mail: stefano.luisi@unisi.it

ABSTRACT

Hysteroscopy is an endoscopic surgical procedure that has become an essential tool to evaluate uterine pathology. It offers a direct visualization of the entire uterine cavity and provides the possibility of performing biopsies on suspected lesions that can be missed by dilatation and curettage (D&C). In most cases, intrauterine lesions can be diagnosed and treated at the same setting as office hysteroscopy ("see and treat"). For example, endometrial polyps can be diagnosed and removed; similarly, intrauterine adhesions can be treated in the outpatient setting without the need for an operating theatre. Today, many hysteroscopic procedures are performed in an outpatient setting. This is due to the feasibility of operative hysteroscopy using saline as distending medium and the endoscopic approach of hysteroscopy and the availability of mini-hysteroscopic endoscopes. There is evidence to suggest that hysteroscopy in an ambulatory setting is preferable for the patient. It avoids complications, allows a quicker recovery time and lowers cost. Advances in technology have led to the development of high-definition endoscopes without compromising optical performance, thereby making hysteroscopy a safe and effective office procedure. The new surgical technology such as bipolar electrosurgery, energy and ablation devices, endometrial sterilization, and morcellators has revolutionized this surgical modality. The development of minimally invasive techniques has completely transformed the approach to the uterine intracavitary pathologies moving from a procedure performed under general anesthesia to an outpatient procedure performed under direct visualization. The therapeutic and diagnostic possibilities of treatment that should belong to every modern gynecologist.

(Cite this article as: Centini G, Troia L, Lazzeri L, Petraglia F, Luisi S. Modern operative hysteroscopy. Minerva Ginecol 2016;68:126-32)

Key words: Hysteroscopy, endoscopy, Surgical techniques, Operative.

Hysteroscopy is an endoscopic surgical procedure that has become an essential tool to evaluate uterine pathology. It offers a direct visualization of the entire uterine cavity and provides the possibility of performing biopsies on suspected lesions that can be missed by dilatation and curettage (D&C). In most cases, intrauterine lesions can be diagnosed and treated at the same setting as office hysteroscopy ("see and treat"). For example, endometrial polyps can be diagnosed and removed; similarly, intrauterine adhesions can be treated in the outpatient setting without the need for an operating theatre. Today, many hysteroscopic procedures are performed in an outpatient setting. This is due to the feasibility of operative hysteroscopy using saline as distending medium and the endoscopic approach of hysteroscopy and the availability of mini-hysteroscopic endoscopes. There is evidence to suggest that hysteroscopy in an ambulatory setting is preferable for the patient. It avoids complications, allows a quicker recovery time and lowers cost. Advances in technology have led to the development of high-definition endoscopes without compromising optical performance, thereby making hysteroscopy a safe and effective office procedure. The new surgical technology such as bipolar electrosurgery, energy and ablation devices, endometrial sterilization, and morcellators has revolutionized this surgical modality. The development of minimally invasive techniques has completely transformed the approach to the uterine intracavitary pathologies moving from a procedure performed under general anesthesia to an outpatient procedure performed under direct visualization. The therapeutic and diagnostic possibilities of treatment that should belong to every modern gynecologist.

Initially hysteroscopy gained a well-established position as second line diagnostic tool after ultrasonographic suspicious of intracavitary abnormalities, but it has been recently

proposed as a first line investigation tool with more and more consents.

Thanks to technological progress hysteroscopy can be proposed as a safe outpatient procedure introducing the concept of Office hysteroscopy and expanding the feasibility examination not only as minimally invasive diagnostic technique, but also enabling the surgeon to perform small interventions through an operative channel such as polypectomy, endometrial biopsy or facilitate subsequent operative hysteroscopy.

Furthermore the same technical progress applied to operative hysteroscopy enlarged the

field of applicability transforming most of the intracavitary abnormalities that just few years before were treated by conventional surgery, such as myomas and uterus septum, in something that belong exclusively to hysteroscopy.

Nowadays office hysteroscopy is a tool that should belong to every modern gynecologist, because it offers to most of the patient a painless and effective treatment that avoids local or general anesthesia, a faster return to normal activity reducing the costs and optimizing of the operating room for major procedures.

History of hysteroscopy

The first reported hysteroscopy was performed for the first time in 1869 by an Italian doctor, Diomedes Pantaleoni, who used the cystoscope of Desormeaux to remove an endometrial polyp in woman with postmenopausal bleeding.¹

During the 50s hysteroscopy was mainly a diagnostic tool with the possibility to remove synechiae with the tip of the instrument and to perform sterilization through the intracavitary injection of sclerosing substances such as silver nitrate.

Cornier *et al.* developed in the 80s a flexible hysteroscope trying to reduce patient's discomfort,^{2, 3} and Gold *et al.* developed for the first time a tool to perform endometrial ablation to treat metrorrhagia with Nd:YAG laser (neodymium-doped yttrium aluminum garnet).⁴ The same author also used the tubal ostium cautery with a cautery probe close to of 90° of angulation was also obtained by introducing hysteroscopic instruments to block the entrance in tube.⁶

During the second half of the twentieth century hysteroscopy underwent significant changes and technical improvements, both in terms of the size of the instruments and distension medium.

The size moved from 11 and 8 mm in diameter in 1934 with Segond, to 4 mm at the end of the 70s as well as CO2 was replaced by saline solution at the end of the '80s and the introduction of continuous flow allowed a

clear vision of the cavity even in the presence of bleeding or secretions.

Finally the introduction of monopolar current and the development of the first resectoscope enlarged the field of application enabling Neuwirth to perform the first hysteroscopic myomectomy in 1981 and Decherney the first resectoscopic ablation in 1983.

In 1995 Ivan Mazzon introduces the use of loops cold for enucleation of myomas G1 (submucosal with intramural component).

Modern outpatient hysteroscopy

The modern outpatient hysteroscopy changed during the 90s with the miniaturization of the instruments that allowed surgeons to perform the procedure in ambulatory setting, the introduction of office hysteroscopy, the introduction of the vaginocolpocystoscopy or "no-touch" technique by Stefano Bettocchi *et al.* in 1997 which significantly reduced the patient's discomfort and allowed to perform hysteroscopy even on virgin or post-menopausal women without anesthesia with a complication rate reported from 0% to 2.4%.^{7, 8}

Nowadays the most commonly used device for office hysteroscopy is a 5 mm diameter hysteroscope with continuous flow introduced with a 2.9 mm and 30° fore-oblique optic. Stefano Bettocchi changed the way to do hysteroscopy modifying the shape of an existing instrument of 6.5 mm from round to oval and introducing a 5 Fr operative channel.

The possibility to introduce operative semi-rigid instrument through a 5 Fr operative channel canceled the distinction between diagnostic and operative hysteroscopy introducing the new concept of "see and treat". For more than a decade the only available instrument were mechanical represented essentially by grasping forceps and scissors that would be used to treat small endometrial polyps, intracavitary uterine synechiae and to make biopsies.^{7, 12}

In 1997 it was also introduced into the market a versatile electrosurgical system dedicated for hysteroscopy (VersaPoint Bipolar Electrosurgical System, Ethicon, Somerville, NJ, USA) that is a high-frequency bipolar gen-

erator and coaxial bipolar electrodes allowing to cut, coagulate, and vaporize the tissues.^{12, 13} This bipolar flexible electrode can be introduced through the working channel of modern hysteroscopes enlarging the types of feasible procedure in an outpatient setting.¹⁴

The introduction of bipolar electrodes involved a changing in the distension medium from the nonionic one (glycine, sorbitol, mannitol) to a simple saline solution and transforming hysteroscopy in safer procedure.¹⁵ The saline solution has proved to be not only associated with a better vision in case of bleeding, a better patients compliance and cost-benefit ratio but it also allows the surgeon to work for a longer time because the patient can bear a large amount of fluid imbalance without the risk of developing hyponatremia and the removal of an endometrial polyps or myomas whose dimensions exceed the diameter of uterine orifice became reality just cutting it in smaller pieces with the bipolar electrode.¹⁶

To increase the size of polyps that may be removed without anesthesia a new hysteroscopic tool has been developed from an existing laparoscopic device, the morcellator. The hysteroscopic morcellator is used in an office setting and fragments the polyp with a rotating blade while a suction device remove the tissue simultaneously. This procedure reduce operative time and patients discomfort.¹⁷

To reduce patients discomfort during gynaecology hysteroscopy, the use of a distension instrument used and a hysteroscopic approach is important not to stimulate the vagal reflex or vagal stimulation. The mechanism of vagal stimulation caused by the manipulation of the peritoneum and the Douglas pouch is one of the fundamental elements in the induction of both pelvic pain that vagal stimulation.

A flow of 200-350 ml/min with a pressure of 70 mmHg or lower is usually enough to have a good distension of the uterine cavity avoiding unnecessary channeling of the tube ("tubal spillage") with subsequent passage of distension medium in the abdominal cavity.

Even if the vaginoscopic approach, making examination well tolerated by almost all patients, has almost completely removed the

need of premedication and/or analgesia to perform hysteroscopy in of cases cervical channel stenosis or operative procedure additional analgesic medicaments might be needed.

Anesthetic techniques for the outpatient procedure include topical lidocaine, intra-uterine lidocaine and the traditional or deep paracervical block.²⁰ Analgesia, in the form of paracetamol or anti-inflammatory drugs may be used for outpatient hysteroscopy operations: Diclofenac sodium is one that has shown greater efficacy.

The use of laser technology in gynecology has become widespread since the CO2 laser was initially used by *et al.* in 1973 for treatment of cervical erosions, then for the treatment of cervical intraepithelial neoplasia and microdissection of the fallopian tube.²¹⁻²³ Since then, the advanced laser technology has made possible several other types of laser with low average power.

The most common lasers in gynecology are Carbon Dioxide (CO2) and YAG. Each instrument produces the waves of specific wavelength giving a characteristic color (monochromatism). Some of these lasers use a flexible fiber that can be passed easily through the operating channel of the hysteroscope. The fiber has been attached to the operating hysteroscope. The use of laser energy for the treatment of uterine fibroids and menorrhagia was first reported in 1981 and hysteroscopic procedures that can be accomplished with the laser include removal of fibroids and polyps, transection of uterine septa, lysis of adhesions, and endometrial ablation.²⁴

Fields of application

Uterine myomas are the most common pelvic tumors of the female genital tract. Even if usually asymptomatic, these benign masses have been associated with a number of clinical issues such as abnormal uterine bleeding (AUB), heavy menstrual bleeding (HMB), infertility, recurrent pregnancy loss, especially when these masses are submucous.²⁵

Golden standard treatments for symptomatic submucous fibroids have long been con-

sidered their laparotomic removal or a total hysterectomy,²⁶⁻³⁰ according to the desire of preserving fertility. However, the laparotomic approach requires the opening of the uterine cavity causing often pelvic post-operative adhesions, altering the likelihood of subsequent conception³¹ and increasing the complications of spontaneous delivery. The development of endoscopy has made these fibroids accessible and removable from the inner surface of uterus.³² Hysteroscopic myomectomy is now the standard uterus-sparing surgical procedure for treating submucous fibroids. Whereas hysteroscopic myomectomy of lesions lying entirely or mostly in the uterine cavity has become a standard technique, there is no consensus regarding hysteroscopic excision of submucous fibroids with a major intramural component. Although some reported an increased need for repeated resections and reduced success rate, others found no effect of the intramural extension on long-term outcome.^{28, 33}

The morcellation of the fibroid by IUM (intra uterine morcellator) represents a new alternative technique which is performed with heat, coagulation or vaporization. The main advantage is to leave tissue unharmed for histological examination. Recently, *et al.*¹⁹ have shown that morcellation by IUM was effective and faster than conventional resectoscopy for the treatment of fibroid G0.

The possibility to perform an outpatient setting introduced the ability to minimize surgical steps to be performed in the operating room, as the recent development of the technique of Partial Myomectomy (P.P.I.U.M). The OP technique is essentially to facilitate the hysteroscopic removal of submucosal myoma with an intramural component (G1-G2) where the pseudocapsul is transected facilitating the intracavitary herniation.³⁴

Hysteroscopy has a primary role to increase fertility in most of the congenital and acquired problems affected women in fertility age, allowing defining that diagnostic and operative hysteroscopy is a rapid and safety technology to improve fertility.

Uterine pathologies, including congenital or

acquired lesions, have been reported in 21 to 47% of patients undergoing in vitro fertilization cycles. Hysteroscopy can diagnose and remove polyps, submucosal myomas distorting uterine cavity, reduce cervical stenosis, septa and adhesions, and finally diagnose chronic asymptomatic inflammation.

Some studies have started to evaluate the importance of subjecting the patient to an office hysteroscopy before ART, considering patient compliance, possible side effects and complications of the procedure. It is made that even office hysteroscopy could be a part of the infertility workup before ART also in patients with normal HSG.³⁵ This is especially relevant in patients with prior failed ART cycles.³⁵

Hysteroscopy can be there also to perform sterilization in an outpatient setting to reduce the risks associated with general anesthesia and the cost of the length of hospital

pressure. The first device for hysteroscopic sterilization authorized by the FDA in October 2002.³⁶ It is a small flexible spiral with a length 40 mm-diameter 0.8 mm) made of nitinol, stainless steel and polyethylene terephthalate). The procedure is performed in vaginoscopy with speculum and tenaculum using a rigid hysteroscope with the diameter smaller than 5 mm. The micro device is released and expands staring inside the tubes stimulating an inflammatory reaction that causes a permanent fibrotic occlusion of the lumen by three months.³⁷ It takes between 15-25 minutes to be performed and recent studies reported a success rate higher than 90%.³⁸⁻⁴⁰

Another therapeutic alternative that comes out from the recent development of hysteroscopy is to treat abnormal uterine bleeding. Dysfunctional bleeding is always a major gynecological problem, particularly in women over 40, and is not easy to resolve with medical treatment.⁴¹ In fact, hormonal medication often has a transitory effect and cannot be administered for long periods of time.

The possibility to ablate the endometrium is a minimally invasive approach that found its

main application in those patients resistant to medical therapy and contraindication to surgery or for those who want to preserve their uterus.^{42, 43}

The first generation techniques are implemented under direct vision of uterine cavity, for transcervical, with use of a loop electrical and/or rollerball. The outcomes of these techniques, difficult to learn, are strictly dependent from the experience of the surgeon.^{44, 45} The second generation devices has been essentially developed to reduce the failure rate and transform the procedure in something more simple and much less dependent from the surgeon allowing in some cases to perform the procedure in an out-patients setting. Trying to improve the efficacy lot of different techniques has been employed such radio frequency, microwaves and hydrothermal ablation.^{46, 47}

The radio frequency ablation tool uses a triangle mesh adaptable to the endometrial cavity a generator that transmits radio waves (500 kHz, 180 watts) through a probe of 8 mm.

A tissue impedance limit of 50 ohms, defined by the system and its tissue myometry determines the end of intervention, the duration of which is less than 2 minutes. Sure system can be applied for uterine cavity with dimensions of between 8 and 11 cm. The success rate at one year is 97%, amenorrhea rushes in 43% of cases.^{49, 50}

The microwave technology (MICOSE) Microwave Endometrial Ablation (MICOSE) system, Minitouch, is based on the thermal (80-100°C) produced by microwave (9.2 GHz) emitted by a probe of 8 mm. The thermal necrosis extending to 6 mm in the endometrial surface, the duration of the procedure is approximately 2 minutes. Require cervical dilation and therefore local anesthesia; the success rate at one year is 97% and amenorrhea was reported in 33-53% of cases.^{49, 50}

This device is the only approved in women with submucosal myomas of diameter >3 cm or with an endometrial thickness >14 mm; even patients with low C-section can be treated if the thickness of the scar, measured with TVUS, is >8 mm.

Hydrothermoablation (HTA) differs from the other second generation devices to be a hysteroscopic endometrial ablation procedure executes with vision, based on the use of a hysteroscope to 3 mm with the outer shirt of 7.8 mm. The technique consists in endometrial instillation closed-loop and continuous saline pre-heated to 80-90° C, for a period of 10 minutes, at pressures (40-50 mm/Hg) lower than those sufficient to force the tubal passage (60-70 mm/Hg). The liquid circulates freely in the uterine cavity, reaching also the fallopian tubes and thus acting on the entire endometrial surface.

It requires local anesthesia and endometrial preparation; the uterine cavity should measure <12 cm, but for a uterus >12 cm can be treated. The success rate at one year is 97% with amenorrhea in 40-60% of cases.^{49, 51}

Despite the good effectiveness of hysteroscopy in the diagnosis of uterine cavity impaired by an endometrial thinness that may hide small subcavitary lesions. This small disadvantage has been quickly overtaken planning the procedure during the early proliferative phase of the menstrual cycle or controlling the endometrial thickness with hormonal drugs.

In recent studies, pretreatment of the endometrium for three month with GnRH analogues (GnRH-a) - prior to endometrial ablation has been reported to increase the success rate, as well as to reduce the menstrual blood flow, accounting for a significantly higher postoperative amenorrhea rate. The advantages are also improved hysteroscopic view, reduced blood loss, absorption of uterine distending fluid. The aim of pretreatment is not only to obtain a thin endometrium but also to reduce the size and vascularization of myomas being treated, with advantages for operating time. Prior to hysteroscopic myoma resection, pretreatment with GnRH-a may be particularly indicated for all myomas with a diameter of more than 3 cm and/or with an intramural portion, or for patients suffering from secondary anemia.⁵²

Hysteroscopic examination may also be preceded by a drug treatment involves the use of drugs such as progestins or danazol, which

have effects consistent with the treatment with GnRH, but fewer side effects. A short pretreatment with combined oral contraceptive containing dienogest (DNG) and estradiol valerate (E₂V) seems to have a favorable impact on endometrium, which can result in an improvement of the overall results of office hysteroscopy.⁵³

Conclusions

Hysteroscopy arose as a diagnostic technique but then it also became an alternative surgical technique for many diseases, offering therapeutic and irreplaceable possibilities of treatment, avoiding major surgery on the one hand and allowing the correction of several pathologies on the other hand.

In conclusion, the modern development of hysteroscopy completely transformed the approach to the uterine intracavitary pathologies moving from a blind procedure under general anesthesia to an outpatient procedure performed under direct visualization. These changes improved dramatically the treatment effectiveness and reduced the costs and, not least enhanced patient's comfort and satisfaction.

References

- Bakour SH, Jones SE. Office hysteroscopy: Evidence for diagnosis and therapy. *Best Pract Res Clin Obstet Gynecol* 2005;19:1-5.
- Cornier E. Office hysteroscopy: treatment of persistent uterine leiomyomas using the CO₂ laser. *J Gynecol Obstet (Paris)* 1997;177:10-12.
- Lin B, Ma M, Tomomatsu T, Iwami H, Nakamura T. [The development of a new flexible hysteroscope and its clinical application]. *Nippon Sanka Fujikaikai Zasshi* 1984;84:49-54 [Article in Japanese].
- Goldrath MH, Fuller TA, Segal S. Laser photovaporization of endometrium for the treatment of menorrhagia. *Am J Gynecol* 1981;140:14-9.
- Neuwirth RS. Tubal sterilization via laparoscopy and hysteroscopy. *Acta Eur Fertil* 1975;6:265-9.
- Reed TP 3rd, Erb R. Hysteroscopic tubal occlusion with silicone rubber. *Obstet Gynecol* 1983;61:388-92.
- Valle RF. Isteroscopia ambulatoriale. In: Baggish M S, Valle RF, Guedj H, editors. *Isteroscopia. Anatomia, fisiologia e patologia dell'utero*. Third edition. Roma: Verducci Editore; 2008.
- Cicinelli E. Diagnostic minihysteroscopy with vaginoscopic approach: rationale and advantages. *J Minim Invasive Gynecol* 2005;12:396-400.
- Bettocchi S, Selvaggi L. A vaginoscopic approach to reduce the pain of office hysteroscopy. *J Am Assoc Gynecol Laparosc* 1997;4:255-8.
- Bettocchi S, Ceci O, Nappi L, Di Venere R, Masciopinto V, Pansini V, et al. Operative office hysteroscopy without anesthesia: analysis of 4863 cases performed with mechanical instruments. *J Am Assoc Gynecol Laparosc* 2004;11:59-61.
- Carluccio MG, Marelllo F, Caliandio D. Office hysteroscopy: pain evaluation by visual analog scale. *J Am Assoc Gynecol Laparosc* 2004;11:S54.
- Kung RC, Vilos GA, Thomas B, Penkin P, Zaltz AP, Stabinsky SA, et al. A new bipolar system for performing operative hysteroscopy in normal saline. *J Am Assoc Gynecol Laparosc* 1999;6:331-6.
- Vilos GA. Intrauterine surgery using a new coaxial bipolar electrode in normal saline solution (tapoint): a pilot study. *Fertil Steril* 1999;72:740-2.
- Bettocchi S, Nappi L, Ceci O. Office hysteroscopy in the treatment of uterine polyps and myomas by using small diameters mechanical instruments. *Gynecol Surg* 2005;2(Suppl 1):10-12.
- Golan A, Sagiv P, Givon S, Glezerman M. Bipolar electric resection: a physiologic solution—a revolution in office hysteroscopy. *J Am Assoc Gynecol Laparosc* 2004;11:103-6.
- Bettocchi S, Di Venere R, Masciopinto V, Pellegrino A. Myomectomy. Treatment of leiomyomas in a minimally invasive way. Can we? *J Minim Invasive Gynecol* 2005;12:399-402.
- Complications of hysteroscopic and uterine morcellator surgery. *Obstet Gynecol Clin North Am* 2005;12:399-42.
- Dongen H, Erbe M, Wolterbeek R, Trimbos JB, Jaansen FW, et al. A morcellator for removal of intrauterine leiomyomas: a randomized controlled pilot study on residents in training. *J Minim Invasive Gynecol* 2005;12:66-71.
- Erbe M, Wolterbeek R, van der Wal AC, van der Wal AC, van der Wal AC, et al. The Intra Uterine Morcellator: a hysteroscopic operating technique to remove uterine polyps and myomas. *J Minim Invasive Gynecol* 2005;12:62-6.
- Yuen PM. Use of diclofenac as an analgesic in outpatient hysteroscopy: a randomized, double blind, placebo-controlled study. *Fertil Steril* 2001;76:1070-2.
- Kaplan I, Goldman J, Ger R. The treatment of erosions of the uterine cervix by means of the CO₂ laser. *Obstet Gynecol* 1973;41:795-6.
- Bellina JH. Carbon dioxide lasers in gynecology. *Obstet Gynecol Annu* 1977;6:371-91.
- Bellina JH. Microsurgery of the fallopian tube with the carbon dioxide laser: Analysis of 230 cases with a two-year follow-up. *Lasers Surg Med* 1983;3:255-60.
- Goldrath MH, Fuller TA, Segal S. Laser photovaporization of endometrium for the treatment of menorrhagia. *Am J Obstet Gynecol* 1981;140:9-14.
- AAGL Practice Report: Practice Guidelines for the Diagnosis and Management of Submucous Leiomyomas. *J Minim Invasive Gynecol* 2012;19:152-71.
- Garcia CR, Turek RW. Submucosal leiomyomas and infertility. *Fertil Steril* 1984;42:16-9.
- Smith DC, Uhlir JK. Myomectomy as a reproductive procedure. *Am J Obstet Gynecol* 1990;162:1476-9.
- Verkauf BS. Myomectomy for fertility enhancement and preservation. *Fertil Steril* 1992;58:1-15.
- Sudik R, Husch K, Steller J, Daume E. Fertility and pregnancy outcome after myomectomy in sterility patients. *Eur J Obstet Gynecol Reprod Biol* 1996;65:209-14.
- Campo S, Campo V, Gambadauro P. Short-term and long-term results of resectoscopic myomectomy with and without pretreatment with GnRH analogs in premeno-

- pausal women. *Acta Obstet Gynecol Scand* 2005;84:756-60.
31. Berkeley AS, DeCherney AH, Polan ML. Abdominal myomectomy and subsequent fertility. *Surg Gynecol Obstet* 1983;156:319-22.
 32. Walker CL, Stewart EA. Uterine fibroids: the elephant in the room. *Science* 2005;308:1589-92.
 33. Cheng YM, Lin BL. Modified sonohysterography immediately after hysteroscopy in the diagnosis of submucous fibroid. *J Am Assoc Gynecol Laparosc* 2002;9:24-8.
 34. Bettocchi S, Di Spiezo Sardo A, Ceci O, Nappi L, Guida M, Greco E, *et al*. A new hysteroscopic technique for the preparation of Partially Intramural Myomas in office setting (OPPluM technique): A Pilot Study. *J Minim Invasive Gynecol* 2009;19:748-54.
 35. El-Mazny AI, Abou-Salem N, El-Sherbiny W, Saber W. Outpatient hysteroscopy: a routine investigation before assisted reproductive techniques? *Fertil Steril* 2011;95:272-6.
 36. Shavell VI, Abdallah ME, Shade GH Jr, Diamond MP, Berman JM. Trend in sterilization since the introduction of Essure hysteroscopic Sterilization. *J Minim Invasive Gynecol* 2009;16:22-7.
 37. Ubeda A, Labastida R, Dexeus S. Essure: a new device for hysteroscopic tubal sterilization in an outpatient setting. *Fertil Steril* 2004;82:196-9.
 38. Conceptus, Inc. ESSURE System; [Internet]. Available from: <http://www.conceptus.com> [cited 2016, Feb 29].
 39. Kerin J, Cooper JM, Price T, Herendael BJ, Cayuela-Font E, Cher D, *et al*. Hysteroscopic Sterilization using a micro-inset device: results of a multicultural Phase III Study. *Hum Reprod* 2003;18:1223-30.
 40. Gerritse MB, Veersema S, Timmermans A, Brölmann HA. Incorrect position of Essure microinserts 3 months after successful bilateral placement. *Fertil Steril* 2009;91:e1-e5.
 41. Mais V, Cossu E, Angioni S, Piras B, Floris L, *et al*. Abnormal uterine bleeding: medical treatment with vaginal danazol and five-year follow-up. *J Am Assoc Gynecol Laparosc* 2004;11:340-3.
 42. NICE guideline CG44 Heavy menstrual bleeding. *January 2007*.
 43. Osei E, Tharmaratnam S, Opemuyi I, Cochrane G. Laser endometrial ablation with the neodymium: yttrium-aluminium garnet (Nd-YAG) laser: a review of ninety consecutive patients. *Acta Obstet Gynecol Scand* 1995;74:619-23.
 44. Goldrath MH, Fuller TA, Segal S. Laser photo vaporization of endometrium for the treatment of menorrhagia. *Am J Obstet Gynecol* 1981;140:14-9.
 45. Vancaillie TG. Electrocoagulation of the endometrium with the ball-end resectoscope. *Obstet Gynecol* 1989;74:425-7.
 46. McGurgan P, O'Donovan P. Second-generation endometrial ablation – an overview. *Best Pract Res Clin Obstet Gynaecol* 2007;21:931-45.
 47. Della Badia C, Nyirjesy P, Atogho A. Endometrial ablation devices: review of a manufacturer and user facility device experience database. *J Minim Invasive Gynecol* 2007;14:436-41.
 48. Baskett TF, Clough H, Scott N. Bipolar radiofrequency endometrial ablation: a review of 200 cases. *J Obstet Gynaecol Can* 2004;106:47-50.
 49. Bradley LD. New endometrial ablation techniques for treatment of menorrhagia. *Technol Int* 2004;12:161-70.
 50. Cooper JM, Price T, Fortin G, Mack SA, Plentl MB. Microinset endometrial ablation for menorrhagia: a randomized trial. *Obstet Gynecol* 2004;11:394-400.
 51. Sills M. Multicenter evaluation of endometrial ablation with the hydrothermal rollerball for treatment of menorrhagia. *J Am Assoc Gynecol Laparosc* 2004;11:659-67.
 52. H1, Lethaby A. Reproductive endometrial thinning agents before assisted reproduction: a systematic review. *Cochrane Database Syst Rev*. 2013 Nov 15;11:CD009252.
 53. Biffoni M, Spiezo Sardo A, De Rosa N, Greco E, Spineca L, Carlo C, *et al*. The use of an oral contraceptive containing estradiol valerate and dienogest before hysteroscopic endometrial ablation: a feasibility study. *Gynecol Endocrinol* 2012;28:949-55.

Conflicts of interest.—The authors declare that there is no conflict of interest with any financial organization regarding the material discussed in the manuscript.

Article first published online January 14, 2016.